MicroRNA-based therapeutics for cancer

BioDrugs

Volumn 23, Issue 1, 2009, Pages 15-23

  Wang, Vivien ^a   Wu, Wei ^b,c  

^a Evanston Northwestern Hospital   (United States)

^b Genome Medicine Research   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; MICRORNA; NANOPARTICLE; VIRUS VECTOR;

CANCER GENE THERAPY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SAFETY; GENE CONTROL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; ONCOGENES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 64149121172     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200923010-00002     Document Type: Review

References (84)

1. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by micro RNAs: are the answers in sight? Nat Rev Genet 2008 Feb; 9 (2): 102-14
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993 Dec 3; 75 (5): 843-54
3. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide Let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000 Feb 24; 403 (6772): 901-6
4. Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science 2001 Oct 26; 294 (5543): 853-8
5. Lau NC, Lim LP, Weinstein EG, et al. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001 Oct 26; 294 (5543): 858-62
6. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001 Oct 26; 294 (5543): 862-4
7. Wellcome Trust Sanger Institute. miRBase sequence database, release 11.0, April 2008 [online]. Available from URL: http://microrna.sanger.ac.uk/sequences [Accessed 2009 Jan 16]
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 Jan 23; 116 (2): 281-97
9. Kato M, Slack FJ. microRNAs: small molecules with big roles: C. elegans to human cancer. Biol Cell 2008 Feb; 100 (2): 71-81
10. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005 Jun 9; 435 (7043): 828-33
11. O'Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005 Jun 9; 435 (7043): 839-43
12. Zhu S, Wu H, Wu F, et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008 Mar; 18 (3): 350-9
13. Yu F, Yao H, Zhu P, et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007 Dec 14; 131 (6): 1109-23
14. Wellcome Trust Sanger Institute. The Cancer Genome Project [online]. Available from URL: http://www.sanger.ac.uk/genetics/CGP/CellLines/ [Accessed 2009 Jan 16]
15. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998 Feb 19; 391 (6669): 806-11
16. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the hetero-chronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993 Dec 3; 75 (5): 855-62
17. Grivna ST, Beyret E, Wang Z, et al. A novel class of small RNAs in mouse spermatogenic cells. Genes Dev 2006 Jul 1; 20 (13): 1709-14
18. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature Rev Cancer 2006 Nov; 6 (11): 857-66
19. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004 Mar 2; 101 (9): 2999-3004
20. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 2004 Aug 10; 101 (32): 11755-60
21. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the Let-7 microRNA family. Cell 2005 Mar 11; 120 (5): 635-47
22. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005 Jun 9; 435 (7043): 834-8
23. Ota A, Tagawa H, Karnan S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004 May 1; 64 (9): 3087-95
24. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005 Nov 1; 65 (21): 9628-32
25. Takakura S, Mitsutake N, Nakashima M, et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci 2008 Jun; 99 (6): 1147-54
26. Lu Z, Liu M, Stribinskis V, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008 Jul 17; 27 (31): 4373-9
27. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006 Mar; 9 (3): 189-98
28. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006 Mar 24; 124 (6): 1169-81
29. Lum AM, Wang BB, Li L, et al. Retroviral activation of the mir-106a microRNA cistron in T lymphoma. Retrovirology 2007; 4: 5
30. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008 Jan; 13 (1): 48-57
31. Park SM, Shell S, Radjabi AR, et al. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 2007 Aug; 6 (21): 2585-90
32. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the Let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004 Jun 1; 64 (11): 3753-56
33. Hua Z, Lv Q, Ye W, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE 2006; 1: e116
34. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005 Sep 27; 102 (39): 13944-9
35. Taguchi A, Yanagisawa K, Tanaka M, et al. Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res 2008 Jul 15; 68 (14): 5540-5
36. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006 Sep; 38 (9): 1060-5
37. Foshay KM, Gallicano GI. miR-17 family miRNAs are expressed during early mammalian development and regulate stem cell differentiation. Dev Biol. Epub 2008 Dec 3
38. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastro-enterology 2007 Aug; 133 (2): 647-58
39. Zhu S, Si ML, Wu H, et al. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007 May 11; 282 (19): 14328-36
40. Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. On-cogene 2008 Apr 3; 27 (15): 2128-36
41. Gabriely G, Wurdinger T, Kesari S, et al. MiR-21 promotes glioma invasion by targeting MMP regulators. Mol Cell Biol 2008 Sep; 28 (17): 5369-80
42. Sayed D, Rane S, Lypowy J, et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell 2008 Aug; 19 (8): 3272-82
43. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006 Feb 14; 103 (7): 2257-61
44. Gironella M, Seux M, Xie MJ, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A 2007 Oct 9; 104 (41): 16170-5
45. Eis PS, Tam W,SunL, etal. Accumulationof miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 2005 Mar 8; 102 (10): 3627-32
46. Weiss GJ, Bemis LT, Nakajima E, et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 2008 Jun; 19 (6): 1053-9
47. Chen R, Alvero AB, Silasi DA, et al. Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene 2008 Aug 7; 27 (34): 4712-23
48. Kuehbacher A, Urbich C, Dimmeler S. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci 2008 Jan; 29 (1): 12-5
49. Venturini L, Battmer K, Castoldi M, et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 2007 May 15; 109 (10): 4399-405
50. Frankel LB, Christoffersen NR, Jacobsen A, et al. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008 Jan 11; 283 (2): 1026-33
51. Tsuda N, Kawano K, Efferson CL, et al. Synthetic microRNA and double-stranded RNA targeting the 3'-untranslated region of HER-2/neu mRNA inhibit HER-2 protein expression in ovarian cancer cells. Int J Oncol 2005 Nov; 27 (5): 1299-306
52. Weidhaas JB, Babar I, Nallur SM, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007 Dec 1; 67 (23): 11111-6
53. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The Let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007 Aug 15; 67 (16): 7713-22
54. Chung KH, Hart CC, Al-Bassam S, et al. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res 2006; 34 (7): e53
55. McLaughlin J, Cheng D, Singer O, et al. Sustained suppression of Bcr-Abl-driven lymphoid leukemia bymicroRNA mimics. Proc Natl Acad SciUS A 2007 Dec 18; 104 (51): 20501-6
56. Liang Z, Wu H, Reddy S, et al. Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun 2007 Nov 23; 363 (3): 542-6
57. Li Z, Zhan W, Wang Z, et al. Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis. Biochem Biophys Res Commun 2006 Sep 15; 348 (1): 229-37
58. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther 2006 Mar; 13(6): 496-502
59. Wahlestedt C, Salmi P, Good L, et al. Potent and nontoxic antisense oligo-nucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A 2000 May 9; 97 (10): 5633-8
60. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 isan antiapoptotic factor in human glioblastoma cells. Cancer Res 2005 Jul 15; 65 (14): 6029-33
61. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2007 Apr 26; 26 (19): 2799-803
62. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006 Jun; 130 (7): 2113-29
63. Corsten MF, Miranda R, Kasmieh R, et al. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 2007 Oct 1; 67 (19): 8994-9000
64. Krutzfeldt J, Rajewsky N, BraichR, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005 Dec 1; 438 (7068): 685-9
65. Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007 Oct; 25 (10): 1149-57
66. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007 Sep; 4 (9): 721-6
67. Esquela-Kerscher A, Trang P, Wiggins JF, et al. The Let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008 Mar 15; 7 (6): 759-64
68. Lu PY, Xie F, Woodle MC. In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 2005; 54: 117-42
69. Abbas-Terki T, Blanco-Bose W, Deglon N, et al. Lentiviral-mediated RNA interference. Hum Gene Ther 2002 Dec 10; 13 (18): 2197-201
70. Tong AW. Small RNAs and non-small cell lung cancer. Curr Mol Med 2006 May; 6 (3): 339-49
71. Fenske DB, Chonn A, Cullis PR. Liposomal nanomedicines: an emerging field. Toxicol Pathol 2008; 36 (1): 21-9
72. Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008 May;26 (5): 561-9
73. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003 Mar; 33 (3): 401-6
74. Liu TC, Thorne SH, Kirn DH. Oncolytic adenoviruses for cancer gene therapy. Methods Mol Biol 2008;434:243-58
75. Zufferey R, Nagy D, Mandel RJ, et al. Multiply attenuated lentiviral vectorachieves efficient gene delivery in vivo. Nat Biotechnol 1997 Sep;15 (9): 871-5
76. Stegmeier F, Hu G, Rickles RJ, et al. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A 2005 Sep 13; 102 (37): 13212-7
77. Tiscornia G, Tergaonkar V, Galimi F, et al. CRE recombinase-inducible RNA interference mediated by lentiviral vectors. Proc Natl Acad Sci U S A 2004 May 11; 101 (19): 7347-51
78. Bisht S, Feldmann G, Koorstra JB, et al. In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther 2008 Dec; 7 (12): 3878-88
79. Michigan Nanotechnology Institute for Medicine and Biological Sciences. DNA linking-novel chemistry [online]. Available from URL: http://nano.med.umich. edu/Platforms/DNA-Linking-Novel-Chemistry.html [Accessed 2009 Jan 13]
80. Sah DW. Therapeutic potential of RNA interference for neurological disorders. Life Sci 2006 Oct 4; 79 (19): 1773-80
81. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006 May 25; 441 (7092): 537-41
82. John M, Constien R, Akinc A, et al. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 2007 Oct 11; 449 (7163): 745-7
83. McBride JL, Boudreau RL, Harper SQ, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A 2008 Apr 15; 105 (15): 5868-73
84. Cejka D, Losert D, Wacheck V. Short interfering RNA (siRNA): tool or therapeutic? Clin Sci (Lond) 2006 Jan; 110 (1): 47-58